Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 9/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537753 | 0.90 | RPS6KA3 (0.51) | RPS6KA3SLC22A12NR1H2 | |
| SCHEMBL6732156 | 0.88 | PTGS2 (0.44) | RPS6KA3PTGS2SLC22A12ABL1KIF11 | |
| SCHEMBL6732776 | 0.87 | RPS6KA3 (0.52) | RPS6KA3PTGS2SLC22A12ABL1KIF11 | |
| SCHEMBL7047515 | 0.86 | PTGS2 (0.42) | RPS6KA3PTGS2SLC22A12ALOX5APFEN1 | |
| SCHEMBL7537413 | 0.86 | PTGS2 (0.42) | RPS6KA3PTGS2SLC22A12ALOX5APFEN1 | |
| SCHEMBL7111106 | 0.85 | SLC22A12 (0.54) | RPS6KA3PTGS2SLC22A12ALOX5APFEN1 | |
| SCHEMBL7537280 | 0.84 | RPS6KA3 (0.58) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL7045230 | 0.83 | RPS6KA3 (0.57) | RPS6KA3PTGS2SLC22A12ALOX5APFEN1 | |
| SCHEMBL7546134 | 0.83 | RPS6KA3 (0.61) | RPS6KA3PTGS2SLC22A12 | |
| SCHEMBL7541466 | 0.83 | RPS6KA3 (0.48) | RPS6KA3PTGS2SLC22A12ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | RPS6KA3 1119/4885PTGS2 5/4885SLC22A12 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.